- Oral, intranasal, and subcutaneous routes of sumatriptan administration are contraindicated in patients with severe hepatic impairment.

- It is contraindicated in patients receiving concurrent MAO type A inhibitors or within two weeks of discontinuing an MAO type A inhibitor.

- Patients with signs and symptoms of ischemic heart disease are relatively contraindicated to use sumatriptan. Ischemic heart diseases include coronary artery vasospasm, myocardial infarction, prinzmetal angina, and angina pectoris.

- Sumatriptan also is contraindicated in patients who use ergotamine and another 5-HT1 agonist concurrently.

- Patients with peripheral vascular disease (also, ischemic bowel disease), cerebrovascular syndromes, or uncontrolled hypertension have a contraindication to sumatriptan.